日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Individualizing Follow-Up Strategies in High-Grade Soft Tissue Sarcoma with Flexible Parametric Competing Risk Regression Models

利用灵活的参数竞争风险回归模型制定高级别软组织肉瘤的个体化随访策略

Smolle, Maria Anna; Sande, Michiel van de; Callegaro, Dario; Wunder, Jay; Hayes, Andrew; Leitner, Lukas; Bergovec, Marko; Tunn, Per-Ulf; van Praag, Veroniek; Fiocco, Marta; Panotopoulos, Joannis; Willegger, Madeleine; Windhager, Reinhard; Dijkstra, Sander P D; van Houdt, Winan J; Riedl, Jakob M; Stotz, Michael; Gerger, Armin; Pichler, Martin; Stöger, Herbert; Liegl-Atzwanger, Bernadette; Smolle, Josef; Andreou, Dimosthenis; Leithner, Andreas; Gronchi, Alessandro; Haas, Rick L; Szkandera, Joanna

Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone

目前关于地诺单抗在骨巨细胞瘤中的应用现状及未解之谜

Gaston, Czar Louie; Grimer, Robert J; Parry, Michael; Stacchiotti, Silvia; Dei Tos, Angelo Paolo; Gelderblom, Hans; Ferrari, Stefano; Baldi, Giacomo G; Jones, Robin L; Chawla, Sant; Casali, Paolo; LeCesne, Axel; Blay, Jean-Yves; Dijkstra, Sander P D; Thomas, David M; Rutkowski, Piotr

Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone

一项开放标签 II 期临床试验中,地诺单抗治疗骨巨细胞瘤患者的手术降期效果

Rutkowski, Piotr; Ferrari, Stefano; Grimer, Robert J; Stalley, Paul D; Dijkstra, Sander P D; Pienkowski, Andrzej; Vaz, Gualter; Wunder, Jay S; Seeger, Leanne L; Feng, Amy; Roberts, Zachary J; Bach, Bruce A

No haploinsufficiency but loss of heterozygosity for EXT in multiple osteochondromas

多发性骨软骨瘤中不存在单倍体不足,但存在 EXT 杂合性缺失

Christianne M A Reijnders, Cathelijn J F Waaijer, Andrew Hamilton, Emilie P Buddingh, Sander P D Dijkstra, John Ham, Egbert Bakker, Karoly Szuhai, Marcel Karperien, Pancras C W Hogendoorn, Sally E Stringer, Judith V M G Bovée